Vaxart Inc (VXRT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vaxart Inc (VXRT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8006
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vaxart Inc (Vaxart) is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus (RSV). Vaxart’s vaccine delivery platform encompasses vector-adjuvant combination, which can be used with many recombinant antigens to develop vaccines for oral administration. The company’s platform approach supports the rapid development of antigen based vaccines. It offers recombinant protein antigens such as marketed influenza, hepatitis B, human papilloma virus (HPV) vaccines, and other recombinant vaccines in industry pipeline. The company also conducts studies for the development of vaccine candidates for other indications. Vaxart is headquartered in South San Francisco, California, the US.

Vaxart Inc (VXRT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Vaxart Raises US$20 Million In Series C Financing Round 11
Vaxart Raises Additional US$4.4 Million In Series B Financing 12
Partnerships 13
Vaxart Enters into Contract with BARDA 13
Merger 14
Aviragen Therapeutics Completes Merger With Vaxart 14
Debt Offering 15
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc – Key Competitors 16
Vaxart Inc – Key Employees 17
Vaxart Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 19
May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 20
Corporate Communications 21
May 01, 2018: Vaxart Names Dr. David Taylor As Chief Medical Officer 21
Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 22
Clinical Trials 23
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma 23
Apr 02, 2018: Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress 24
Jan 31, 2018: Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study 25
Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 26
Oct 26, 2017: Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study 27
Feb 14, 2017: Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine 28
Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir 29
Feb 01, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Vaxart Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Raises US$20 Million In Series C Financing Round 11
Vaxart Raises Additional US$4.4 Million In Series B Financing 12
Vaxart Enters into Contract with BARDA 13
Aviragen Therapeutics Completes Merger With Vaxart 14
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc, Key Competitors 16
Vaxart Inc, Key Employees 17

List of Figures
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Vaxart Inc (VXRT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ObsEva SA (OBSV):企業の財務・戦略的SWOT分析
    ObsEva SA (OBSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sheraton Seoul Palace:企業の戦略・SWOT・財務分析
    Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report Summary Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Red Robin Gourmet Burgers Inc:企業の戦略・SWOT・財務情報
    Red Robin Gourmet Burgers Inc - Strategy, SWOT and Corporate Finance Report Summary Red Robin Gourmet Burgers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Abivax SA (ABVX)-製薬・医療分野:企業M&A・提携分析
    Summary Abivax SA (Abivax) is a biotechnology company that researches, develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases. The company’s pipeline products comprise ABX464, a small molecule against HIV; ABX311 for chikungunya; ABX544 to …
  • SS&C Advent:企業の戦略的SWOT分析
    SS&C Advent - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Norzinc Ltd:企業の戦略・SWOT・財務分析
    Norzinc Ltd - Strategy, SWOT and Corporate Finance Report Summary Norzinc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sangui BioTech International Inc (SGBI):企業の財務・戦略的SWOT分析
    Sangui BioTech International Inc (SGBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Beijing Enterprises Holdings Ltd:企業の戦略・SWOT・財務情報
    Beijing Enterprises Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Beijing Enterprises Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Canada Post Corporation:企業の戦略・SWOT・財務分析
    Canada Post Corporation - Strategy, SWOT and Corporate Finance Report Summary Canada Post Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Prairie Provident Resources Inc (PPR):石油・ガス:M&Aディール及び事業提携情報
    Summary Prairie Provident Resources Inc (Prairie Provident) is an exploration and development company that develops oil and natural gas assets. The company offers exploration and development of oil and natural gas with conventional operations primarily focused in the Western Canadian Sedimentary Bas …
  • East Energy Resources Limited:企業の戦略・SWOT・財務情報
    East Energy Resources Limited - Strategy, SWOT and Corporate Finance Report Summary East Energy Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • University of Colorado Technology Transfer Office-医療機器分野:企業M&A・提携分析
    Summary University of Colorado Technology Transfer Office (CU TTO), a subsidiary of University of Colorado (CU) is a technology transfer service provider that provides development and commercialization processes. The university provides services such as intellectual property management, commercializ …
  • Caltex Australia Ltd (CTX):石油・ガス:M&Aディール及び事業提携情報
    Summary Caltex Australia Ltd (Caltex) is a supplier of transport fuels and convenience retailer. The company purchases, refines, distributes and markets petroleum products. It supplies liquefied petroleum gas (LPG), petrol, diesel, jet fuel, lubricants, greases, fuel oil and specialty products. The …
  • SPR Therapeutics LLC:医療機器:M&Aディール及び事業提携情報
    Summary SPR Therapeutics LLC (SPR Therapeutics) is a medical device company that develops and commercializes neurostimulation products. The company develops therapies for post-surgical pain, neuropathic pain, and musculoskeletal pain. It offers percutaneous peripheral nerve stimulation system for in …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Land O’Lakes, Inc.:企業の戦略・SWOT・財務情報
    Land O'Lakes, Inc. - Strategy, SWOT and Corporate Finance Report Summary Land O'Lakes, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • University of Cambridge-医療機器分野:企業M&A・提携分析
    Summary University of Cambridge (UC) is an educational and research institute that offers undergraduate and graduate studies. The institute offers undergraduate courses in areas of architecture, chemical engineering, classics, computer science. It provides courses such as economics, education, engin …
  • Marico Limited (MARICO):企業の財務・戦略的SWOT分析
    Marico Limited (MARICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Supernus Pharmaceuticals Inc (SUPN):企業の財務・戦略的SWOT分析
    Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆